Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Chembio Diagnostics call volume above normal and directionally bullish » 15:05
07/31/20
07/31
15:05
07/31/20
15:05
CEMI

Chembio Diagnostics

$5.62 /

+0.25 (+4.66%)

Bullish option flow…

Bullish option flow detected in Chembio Diagnostics with 4,223 calls trading, 1.1x expected, and implied vol increasing over 17 points to 237.34%. Aug-20 7.5 calls and Aug-20 5 calls are the most active options, with total volume in those strikes near 2,600 contracts. The Put/Call Ratio is 0.07. Earnings are expected on August 6th.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$5.62 /

+0.25 (+4.66%)

CEMI Chembio Diagnostics
$5.62 /

+0.25 (+4.66%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$5.62 /

+0.25 (+4.66%)

  • 07
    May
CEMI Chembio Diagnostics
$5.62 /

+0.25 (+4.66%)

CEMI Chembio Diagnostics
$5.62 /

+0.25 (+4.66%)

Over a week ago
Options
Chembio Diagnostics call volume above normal and directionally bullish » 15:25
07/14/20
07/14
15:25
07/14/20
15:25
CEMI

Chembio Diagnostics

$5.54 /

+0.89 (+19.14%)

Bullish option flow…

Bullish option flow detected in Chembio Diagnostics with 11,009 calls trading, 4x expected, and implied vol increasing over 24 points to 279.06%. Jul-20 5 calls and Jul-20 7.5 calls are the most active options, with total volume in those strikes near 6,900 contracts. The Put/Call Ratio is 0.03. Earnings are expected on August 4th.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$5.54 /

+0.89 (+19.14%)

CEMI Chembio Diagnostics
$5.54 /

+0.89 (+19.14%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$5.54 /

+0.89 (+19.14%)

  • 07
    May
CEMI Chembio Diagnostics
$5.54 /

+0.89 (+19.14%)

CEMI Chembio Diagnostics
$5.54 /

+0.89 (+19.14%)

Conference/Events
Chembio Diagnostics to host business news update conference call » 07:55
07/07/20
07/07
07:55
07/07/20
07:55
CEMI

Chembio Diagnostics

$4.02 /

-0.15 (-3.60%)

Conference call to…

Conference call to discuss COVID-19 product development plans and preliminary 2Q20 revenue results will be held on July 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

  • 07
    May
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

Conference/Events
Chembio Diagnostics to host business news update conference call » 04:55
07/07/20
07/07
04:55
07/07/20
04:55
CEMI

Chembio Diagnostics

$4.02 /

-0.15 (-3.60%)

Conference call to…

Conference call to discuss COVID-19 product development plans and preliminary 2Q20 revenue results will be held on July 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

  • 07
    May
CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

On The Fly
Fly Intel: After-Hours Movers » 19:08
07/06/20
07/06
19:08
07/06/20
19:08
OTIC

Otonomy

$3.19 /

+0.02 (+0.63%)

, XSPA

XpresSpa

$3.79 /

-0.2 (-5.01%)

, CEMI

Chembio Diagnostics

$4.02 /

-0.15 (-3.60%)

, GLDD

Great Lakes Dredge

$8.85 /

+0.04 (+0.45%)

, PSN

Parsons

$34.56 /

-0.37 (-1.06%)

, KINS

Kingstone Companies

$4.41 /

-0.01 (-0.23%)

, MARK

Remark Holdings

$2.61 /

+0.235 (+9.89%)

, CLLS

Cellectis

$19.04 /

+0.42 (+2.26%)

, TRIB

Trinity Biotech

$2.54 /

+0.23 (+9.96%)

, RVMD

Revolution Medicines

$29.27 /

-1.73 (-5.58%)

, PCRX

Pacira

$54.13 /

+1.93 (+3.70%)

, ARE

Alexandria Real Estate

$164.78 /

-0.08 (-0.05%)

, KMI

Kinder Morgan

$15.20 /

+0.07 (+0.46%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
05/07/20 Piper Sandler
Piper still believes in potential success of three key Otonomy programs
02/07/20 Piper Sandler
Otonomy should be bought ahead of near-term readouts, says Piper Sandler
XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

05/05/20 Wells Fargo
Parsons price target raised to $39 from $33 at Wells Fargo
04/15/20 Benchmark
Parsons initiated with a Buy at Benchmark
04/02/20 Wells Fargo
Parsons price target lowered to $33 from $42 at Wells Fargo
03/30/20 William Blair
Parsons initiated with an Outperform at William Blair
KINS Kingstone Companies
$4.41 /

-0.01 (-0.23%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

06/10/20 Roth Capital
Roth checks point to Kent Services as Remark Holdings distribution partner
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

05/12/20
Fly Intel: Top five analyst initiations
05/11/20 Baird
Cellectis initiated with an Outperform at Baird
03/06/20 Citi
Cellectis price target raised to $16 from $14 at Citi
03/06/20 Goldman Sachs
Cellectis downgraded to Sell from Neutral at Goldman Sachs
TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

05/21/20
Fly Intel: Top five analyst initiations
05/21/20 H.C. Wainwright
Revolution Medicines initiated with a Buy at H.C. Wainwright
03/09/20
Fly Intel: Top five analyst initiations
03/09/20 Cowen
Revolution Medicines initiated with an Outperform at Cowen
PCRX Pacira
$54.13 /

+1.93 (+3.70%)

07/06/20 Needham
Pacira price target raised to $64 from $52 at Needham
07/06/20 Piper Sandler
Pacira price target raised to $65 from $49 at Piper Sandler
07/01/20 RBC Capital
Pacira price target raised to $62 from $56 at RBC Capital
06/30/20 SVB Leerink
Pacira price target raised to $58 from $45 at SVB Leerink
ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

06/08/20 JMP Securities
Alexandria Real Estate resumed with an Outperform at JMP Securities
02/04/20 Mizuho
Alexandria Real Estate assumed with a Buy at Mizuho
12/18/19 JPMorgan
JPMorgan makes 17 REIT rating changes in conjunction with 2020 outlook
12/18/19 RBC Capital
Alexandria Real Estate downgraded to Outperform from Top Pick at RBC Capital
KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

07/06/20 Goldman Sachs
Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs
05/18/20 BofA
Plains All American, GP Holdings cut to Underperform at BofA
04/07/20 Mizuho
Kinder Morgan price target lowered to $20 from $23 at Mizuho
03/24/20 Barclays
Kinder Morgan upgraded to Overweight from Equal Weight at Barclays
TRIB Trinity Biotech
$2.54 /

+0.23 (+9.96%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

OTIC Otonomy
$3.19 /

+0.02 (+0.63%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

KINS Kingstone Companies
$4.41 /

-0.01 (-0.23%)

GLDD Great Lakes Dredge
$8.85 /

+0.04 (+0.45%)

CLLS Cellectis
$19.04 /

+0.42 (+2.26%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

  • 07
    Jul
  • 09
    Jul
  • 07
    May
  • 13
    Feb
  • 07
    Jan
KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

ARE Alexandria Real Estate
$164.78 /

-0.08 (-0.05%)

RVMD Revolution Medicines
$29.27 /

-1.73 (-5.58%)

PSN Parsons
$34.56 /

-0.37 (-1.06%)

PCRX Pacira
$54.13 /

+1.93 (+3.70%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

XSPA XpresSpa
$3.79 /

-0.2 (-5.01%)

MARK Remark Holdings
$2.61 /

+0.235 (+9.89%)

KMI Kinder Morgan
$15.20 /

+0.07 (+0.46%)

CEMI Chembio Diagnostics
$4.02 /

-0.15 (-3.60%)

Earnings
Chembio Diagnostics sees Q2 revenue $4.5M-$4.7M, consensus $11.98M » 16:29
07/06/20
07/06
16:29
07/06/20
16:29
CEMI

Chembio Diagnostics

$4.01 /

-0.16 (-3.84%)

Chembio Diagnostics…

Chembio Diagnostics announced its preliminary estimates of revenue results for Q2. Total revenues for the three months ended June 30 are expected to be in the range of $4.5M-$4.7M, subject to increase by up to an additional $2.5M of revenue with respect to products that were shipped outside the United States during the quarter. While Chembio continues to both ship DPP COVID-19 IgM/IgG systems and pursue additional opportunities outside the United States, it also continues to monitor any potential response by other regulators of the FDA's recent revocation of the EUA for the system. Chembio expects total revenues to be finalized prior to issuance of its financial statements for the quarter and six months ended June 30. Revenues from Chembio's COVID-19-related sales for the quarter are estimated to range from $0.8M-$3.3M, and inclusive in the high end of the range is the additional $2.5M of product shipped outside the United States. Total revenues for the three months ended June 30, 2019 were $9.9M. The decrease in sales is related to a combination of the impact of the COVID-19 pandemic on historical products and markets, as well as the company's shift to address the pandemic with its newly developed product during the three months ended June 30, 2020, combined with seasonally stronger sales of HIV tests to Latin America during the prior year period. Cash and cash equivalents at June 30 are estimated to total approximately $36.6M, including approximately $3.3M of restricted cash and cash equivalents, compared with $11.2M at March 31. The increase in cash and cash equivalents compared to the prior quarter reflect the approximate net proceeds from the company's secondary equity raise of $28.4M, offset by capital expenditures, operating costs, and other items.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

  • 07
    May
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

Hot Stocks
Chembio Diagnostics to submit applications for revised DPP COVID-19 IgM/IgG EUA » 16:22
07/06/20
07/06
16:22
07/06/20
16:22
CEMI

Chembio Diagnostics

$4.01 /

-0.16 (-3.84%)

Chembio Diagnostics…

Chembio Diagnostics announced its plans to submit applications to the FDA for Emergency Use Authorization, or EUA, for a revised version of the DPP COVID-19 IgM/IgG System, a COVID-19 point-of-care serology system, and the DPP COVID-19 Antigen System, a new COVID-19 point-of-care antigen system. The DPP COVID-19 IgM/IgG System consists of Chembio's serology test for COVID-19 and a DPP Micro Reader analyzer. On April 15, 2020, the DPP COVID-19 IgM/IgG System was granted an EUA. Subsequently, the FDA announced performance review based in part on a National Institutes of Health/National Cancer Institute, or NCI, process for the evaluation of COVID-19 serology tests. The NCI report acknowledges that this process, which evaluates COVID-19 serology test sensitivity and specificity using a panel of pre-selected samples, may not be indicative of either performance in the real-world or performance of finger stick blood as used in the Chembio system. On June 16, the FDA revoked the EUA for the DPP COVID-19 IgM/IgG System. As a result, Chembio is revising its system with the objective of meeting the FDA's new criteria, including the use of the NCI process. Chembio expects, based on its development efforts to date, to apply for an EUA for the revised system during Q3.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

  • 07
    May
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

Hot Stocks
Chembio awarded BARDA contract for DPP COVID point of care antigen system » 16:19
07/06/20
07/06
16:19
07/06/20
16:19
CEMI

Chembio Diagnostics

$4.01 /

-0.16 (-3.84%)

Chembio Diagnostics…

Chembio Diagnostics announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority, BARDA,, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The contract is intended to assist Chembio in developing a COVID-19 point-of-care antigen system using Chembio's proprietary DPP technology and requesting a U.S. Food and Drug Administration Emergency Use Authorization, EUA, for the system. The award totals $628,071 and is to be distributed in periodic funding over the next several months. Chembio will use the funds under contract number 75A50120C00138 to accelerate development of its DPP COVID-19 Antigen System, which is expected to consist of a DPP COVID-19 Antigen Assay and DPP Micro Reader and to use a respiratory specimen, such as a nasal or nasopharyngeal swab, to detect SARS-CoV-2 antigens. "We are honored to again partner with BARDA and appreciate their support on a shared mission to expand and decentralize COVID-19 testing," stated Rick Eberly, Chembio's President and Chief Executive Officer. "We believe offering virus detection for diagnosis at the point of care can improve clinical outcomes and play a major role in combating the ongoing pandemic."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

  • 07
    May
CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

CEMI Chembio Diagnostics
$4.01 /

-0.16 (-3.84%)

Over a month ago
Conference/Events
Chembio Diagnostics to host business news update conference call » 16:43
07/02/20
07/02
16:43
07/02/20
16:43
CEMI

Chembio Diagnostics

$4.17 /

+0.89 (+27.13%)

Conference call to…

Conference call to discuss COVID-19 product development plans and preliminary 2Q20 revenue results will be held on July 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

  • 07
    May
CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

CEMI Chembio Diagnostics
$4.17 /

+0.89 (+27.13%)

Options
Largest borrow rate increases among liquid names » 08:45
06/24/20
06/24
08:45
06/24/20
08:45
NKLA

Nikola

$75.08 /

+5.1 (+7.29%)

, ACB

Aurora Cannabis

$13.58 /

-0.12 (-0.88%)

, CLIR

ClearSign Combustion

$1.89 /

-0.12 (-5.97%)

, SRNE

Sorrento Therapeutics

$5.12 /

+0.205 (+4.18%)

, ATNM

Actinium Pharmaceuticals

$0.42 /

-0.017 (-3.91%)

, TXMD

TherapeuticsMD

$1.25 /

+0.05 (+4.18%)

, NEPT

Neptune Wellness

$3.06 /

+0.52 (+20.47%)

, BBBY

Bed Bath & Beyond

$10.23 /

+0.24 (+2.40%)

, CEMI

Chembio Diagnostics

$3.41 /

-0.25 (-6.83%)

, BCLI

BrainStorm

$9.98 /

+0.35 (+3.63%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: (NKLA) 962.76% +4.10, Aurora Cannabis (ACB) 68.78% +2.13, ClearSign Combustion (CLIR) 97.37% +1.79, Sorrento Therapeutics (SRNE) 135.42% +0.91, Actinium Pharmaceuticals (ATNM) 3.47% +0.68, TherapeuticsMD (TXMD) 21.21% +0.64, Neptune Technologies (NEPT) 50.80% +0.53, Bed Bath & Beyond (BBBY) 6.42% +0.47, Chembio Diagnostics (CEMI) 3.39% +0.40, and BrainStorm (BCLI) 11.12% +0.40.

ShowHide Related Items >><<
TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

CLIR ClearSign Combustion
$1.89 /

-0.12 (-5.97%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ATNM Actinium Pharmaceuticals
$0.42 /

-0.017 (-3.91%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 JPMorgan
CNH Industrial price target raised to $8 from $6.50 at JPMorgan
06/22/20 JPMorgan
JPMorgan starts 'fully valued' Nikola with Neutral, $45 price target
06/22/20 JPMorgan
Nikola initiated with a Neutral at JPMorgan
ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

06/24/20 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/22/20 CIBC
Aurora Cannabis price target raised to C$24 from C$14 at CIBC
05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Jefferies
Aurora Cannabis downgraded to Underperform from Hold at Jefferies
CLIR ClearSign Combustion
$1.89 /

-0.12 (-5.97%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$0.42 /

-0.017 (-3.91%)

06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

05/19/20
Fly Intel: Top five analyst downgrades
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral on COVID disruptions at JPMorgan
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral from Overweight at JPMorgan
05/07/20 H.C. Wainwright
TherapeuticsMD price target lowered to $5 from $6 at H.C. Wainwright
NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

01/31/20 Cowen
Neptune Wellness initiated with a Market Perform at Cowen
BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
03/23/20 Odeon Capital
Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.